MO6-1 Real-world treatment outcomes of metastatic pancreatic cancer in Japan: Tokushukai REAl-world Data project 03 (TREAD 03)

Rai Shimoyama,Yoshinori Imamura,Kiyoaki Uryu,Takahiro Mase,Yoshiaki Fujimura,Maki Hayashi,Megu Ohtaki,Keiko Otani,Nobuaki Shinozaki,Hironobu Minami

Annals of Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Gemcitabine (GEM) plus nub-paclitaxel (GnP) and FOLFIRINOX (FFX) have become established treatment for metastatic pancreatic cancer (mPC). The aim of this study was to investigate prognostic factors and temporal trends in treatment pattern for overall survival (OS) in a real-world setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要